Annals of oncology : official journal of the European Society for Medical Oncology, cilt.28, sa.10, ss.2496-2502, 2017 (SCI Expanded İndekslerine Giren Dergi)
Makale / Tam Makale
Annals of oncology : official journal of the European Society for Medical Oncology
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.